Therapy News and Research

RSS

Targacept, AstraZeneca expand TC-5619 development program to include ADHD, Alzheimer's disease

Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics (TM), today announced an amendment to its 2005 collaboration agreement with AstraZeneca expanding the TC-5619 development program. In addition to the current development of TC-5619 in cognitive dysfunction in schizophrenia (CDS), the amended terms provide for parallel development in attention deficit/hyperactivity disorder (ADHD) and potentially Alzheimer's disease.

3 May 2010

BioTime acquires ES Cell International

BioTime, Inc., a biotechnology company that develops and markets products in the field of human stem cells and regenerative medicine, today announced that it has completed its acquisition of the Singapore company ES Cell International Pte Ltd.

3 May 2010

Progress in development of gene therapies for inherited blindness caused by rod degeneration

Veterinary vision scientists at the University of Pennsylvania have safely and successfully used a viral vector in targeting a class of photoreceptors of the retina called rods, a critical first step in developing gene therapies for inherited blindness caused by rod degeneration.

3 May 2010

Inspire Pharmaceuticals reports net loss of $14.8M for first-quarter 2010

Inspire Pharmaceuticals, Inc. announced today financial results for the first quarter ended March 31, 2010, reporting a net loss of $14.8 million or ($0.18) per share.

3 May 2010

Extended hepatitis C treatment increases sustained virological response after liver transplant

Extending hepatitis C treatment for liver transplant patients beyond current standards results in high clearance rates of the hepatitis C virus from the blood, and a low relapse rate, according to a study by Henry Ford Hospital.

3 May 2010

Triple combination therapy with OM, AML, HCTZ more effective at lowering blood pressure

Results of a new study found that the investigational triple combination therapy of olmesartan medoxomil (OM), amlodipine besylate (AML), and hydrochlorothiazide (HCTZ) demonstrated significantly greater mean reductions at week 12 in blood pressure (37.1/21.8 mm Hg versus 27.5 to 30.0/15.1-18.0 mm Hg LS Mean Reductions, P< 0.0001), as compared to corresponding dual combination therapy (dual components).

3 May 2010

EHR with controlled interventions can produce optimal BP control, reduce mortality

Electronic health records with controlled interventions can produce optimal blood pressure control and reduce mortality, according to data presented at the American Society of Hypertension Inc.'s 25th Annual Scientific Meeting and Exposition (ASH 2010).

3 May 2010

Roche's xCELLigence System helps study cell viability, cell death while testing cytotoxic compounds

Monitoring of cell viability and toxicity are critical to many areas of biological and biomedical research. This is true for understanding the molecular and biochemical pathways regulating cell viability, for developing therapeutic agents which modulate cell viability and for identifying potential cytotoxic side effects of potential therapeutic agents.

3 May 2010

RaySearch Laboratories restructures license agreement with Varian Medical Systems

RaySearch Laboratories AB announces today that the license agreement with Varian Medical Systems has been restructured to add one new product, strengthen the collaborative product development efforts, and make it easier to add new capabilities and features to Varian's Eclipse™ treatment planning system. Eclipse software currently incorporates three RaySearch developments, including tools for biological evaluation, biological optimization, and conformal optimization.

3 May 2010

Promising results from combination therapy of pemetrexed concurrent with radiation in lung cancer

The first trial of an important new combination therapy of treatment with the chemotherapy drug pemetrexed concurrent with radiation in lung cancer has delivered promising results, French researchers report at the 2nd European Lung Cancer Conference.

3 May 2010

FDA oks 'vaccine' to treat prostate cancer

Provenge, developed by Dendreon Corporation, is the first approved "treatment that uses a so-called cancer vaccine, a drug that trains the body's own immune system to fight the disease," The New York Times reports.

3 May 2010

Results from VeriStrat biomarker analysis of Phase III trial presented at European Lung Cancer Conference

Results from the VeriStrat biomarker analysis of a multicenter Phase III trial were presented today at the 2nd European Lung Cancer Conference currently being held in Geneva, Switzerland. Results showed that the VeriStrat test identified patients who were likely to have a survival benefit from treatment with erlotinib, a commonly prescribed oral therapy for advanced non-small cell lung cancer.

3 May 2010

Scientists discover three genes linked to development of Paget's disease

Scientists have discovered three genes linked to the development of Paget's disease, a painful bone condition that affects up to one million people in the UK.

3 May 2010

Researchers discover a new driving force behind cancer growth

Researchers from the University of Leeds, UK, the Charit- University Medical School and the Max Delbr-ck Centre for Molecular Medicine (MDC) in Berlin, Germany, have discovered a new driving force behind cancer growth.

3 May 2010

Study shows CBT treatment can help reduce depressive symptoms in mothers

New research suggests that depression is common in disadvantaged mothers, well beyond the postpartum period.

3 May 2010

Health outcomes explored at DDW 2010

Non-alcoholic fatty liver disease, which may soon be the leading indication for liver transplant, is found to be significantly associated with worse transplant outcomes. In addition, a new tool for diagnosing NAFLD represents an alternative to liver biopsy, which is more expensive and prone to complications, and ultrasound and alfafeprotein blood test screening are an effective alternative to CT scan and MRI for patients with cirrhosis at high risk for hepatocellular cancer.

3 May 2010

Smoking can increase risk of second cancer in breast cancer survivors

Women who survive early-stage breast cancer and smoke have an increased chance of developing a new second cancer in their other breast or elsewhere.

3 May 2010

CPMC establishes new Bryan Hemming Cancer Care Center

Being diagnosed with cancer can be devastating for anyone, bringing with it a series of life-changing challenges, both physical and emotional. That's why California Pacific Medical Center is delighted to announce the opening of the Bryan Hemming Cancer Care Center, a one-of-a-kind space offering a wide range of essential support services for patients and their loved ones, all under one roof.

3 May 2010

Vitamin E effective in treating NASH: Study

Vitamin E has been shown effective in treating nonalcoholic steatohepatitis, an obesity-associated chronic liver disease that can lead to cirrhosis, liver cancer, and death. NASH also is related to or a part of type 2 diabetes, lipid disorders and cardiovascular disease.

3 May 2010

NeurogesX announces $40 million royalty financing agreement with Cowen Royalty

NeurogesX, Inc., a biopharmaceutical company focused on developing and commercializing novel pain management therapies, announced today that that it has entered into a $40 million royalty financing agreement with Cowen Healthcare Royalty Partners, L.P. ("Cowen Royalty").

30 Apr 2010

Therapy News and Research

Targacept, AstraZeneca expand TC-5619 development program to include ADHD, Alzheimer's disease

BioTime acquires ES Cell International

Progress in development of gene therapies for inherited blindness caused by rod degeneration

Inspire Pharmaceuticals reports net loss of $14.8M for first-quarter 2010

Extended hepatitis C treatment increases sustained virological response after liver transplant

Triple combination therapy with OM, AML, HCTZ more effective at lowering blood pressure

EHR with controlled interventions can produce optimal BP control, reduce mortality

Roche's xCELLigence System helps study cell viability, cell death while testing cytotoxic compounds

RaySearch Laboratories restructures license agreement with Varian Medical Systems

Promising results from combination therapy of pemetrexed concurrent with radiation in lung cancer

FDA oks 'vaccine' to treat prostate cancer

Results from VeriStrat biomarker analysis of Phase III trial presented at European Lung Cancer Conference

Scientists discover three genes linked to development of Paget's disease

Researchers discover a new driving force behind cancer growth

Study shows CBT treatment can help reduce depressive symptoms in mothers

Health outcomes explored at DDW 2010

Smoking can increase risk of second cancer in breast cancer survivors

CPMC establishes new Bryan Hemming Cancer Care Center

Vitamin E effective in treating NASH: Study

NeurogesX announces $40 million royalty financing agreement with Cowen Royalty

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News